Features For Fellows & Trainees
Continued from page 63
In your opinion, what are the biggest obstacles facing
today’s trainees?
Securing funding to acquire the necessary protected time for research
will be more difficult than ever, given the proposed cuts to National
Institutes of Health (NIH) funding. It is difficult to find positions that
support the research time necessary to achieve independent funding or
expertise.
Simply put, completing a fellowship is not enough to be seen as an
expert. It’s easy for trainees to focus on patient care and forget about
prioritizing devoted time to research, but protected research time is
essential for producing original research.
Based on your experience, what qualities should trainees
look for in a mentor?
Mentorship can really make or break your early career. When
looking for a mentor, choose one with a clear track record of success
mentoring trainees at all levels – not just fellows, but residents and
medical students, as well. This demonstrates that they truly prioritize
and have a passion for trainee education.
Find someone you respect both personally and professionally
because, ideally, you’ll be spending a lot of time with this person.
Ensure that the mentor is academically productive, well-
published, and has secured funding in your area of interest.
VYXEOS™ (daunorubicin and cytarabine) liposome for injection,
for intravenous use
BRIEF SUMMARY OF PRESCRIBING INFORMATION: Consult
the Full Prescribing Information, including BOXED Warning,
for complete product information.
Initial U.S. Approval: 2017
WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN
AND/OR CYTARABINE-CONTAINING PRODUCTS
• VYXEOS has different dosage recommendations than
daunorubicin hydrochloride injection, cytarabine injection,
daunorubicin citrate liposome injection, and cytarabine
liposome injection. Verify drug name and dose prior to
preparation and administration to avoid dosing errors
[see Warnings and Precautions].
INDICATIONS AND USAGE
VYXEOS is indicated for the treatment of adults with newly-diagnosed
therapy-related acute myeloid leukemia (t-AML) or AML with
myelodysplasia-related changes (AML-MRC).
CONTRAINDICATIONS
The use of VYXEOS is contraindicated in patients with the following:
• History of serious hypersensitivity reaction to cytarabine,
daunorubicin, or any component of the formulation [see Warnings
and Precautions].
WARNINGS AND PRECAUTIONS
Do Not Interchange With Other Daunorubicin And/Or
Cytarabine-Containing Products
Due to substantial differences in the pharmacokinetic parameters,
the dose and schedule recommendations for VYXEOS are different
from those for daunorubicin hydrochloride injection, cytarabine injection,
daunorubicin citrate liposome injection, and cytarabine liposome
injection. Verify drug name and dose prior to preparation and
administration to avoid dosing errors. Do not substitute other
preparations of daunorubicin or cytarabine for VYXEOS.
Hemorrhage
Serious or fatal hemorrhage events, including fatal central nervous
system (CNS) hemorrhages, associated with prolonged severe
thrombocytopenia, have occur